Theracurmin (Nano-Curcumin) for Alzheimer's Disease
Also known as: Nano-curcumin, Highly bioavailable curcumin
Theracurmin achieves 27x higher bioavailability than standard curcumin, potentially resolving the clinical translation gap.
Mechanism of Action
Nano-encapsulation enables curcumin to achieve therapeutic brain concentrations for direct amyloid inhibition, NF-κB suppression, tau phosphorylation reduction, and Nrf2 activation. PET imaging confirmed amyloid and tau signal reduction with Theracurmin.
General mechanism: Nano-encapsulated curcumin with 27x bioavailability. NF-κB inhibitor, anti-amyloid, anti-tau, Nrf2 activator at achievable tissue levels.
Current Evidence
UCLA trial (Small et al., AJGP 2018) showed Theracurmin improved memory and reduced amyloid/tau PET signals over 18 months. First curcumin formulation to show PET-confirmed biomarker changes.
Clinical Status: Phase II positive with PET confirmation. Published in peer-reviewed journal.
Safety Profile
Safe. Well-tolerated in clinical trials. Same safety profile as standard curcumin with enhanced absorption.
Key Research Questions
- Can Theracurmin provide disease modification in early AD?
- Does the PET-confirmed amyloid/tau reduction translate to sustained cognitive benefit?